Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 15, Issue 7, 2008, Pages 523-530

  Tarantino, G ^a   Cabibi, D ^a   Camma C ^a   Alessi, N ^a   Donatelli, M ^a   Petta, S ^a   Craxi A ^a   Di Marco, V ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Chronic hepatitis C; Drugs; Eosinophilic infiltrate; Liver biopsy; Liver fibrosis; Liver steatosis

Indexed keywords

ADULT; ARTICLE; CELL INFILTRATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; EOSINOPHIL; FATTY LIVER; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; LEUKOCYTE; LIVER; LIVER BIOPSY; LIVER FIBROSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; SCORING SYSTEM;

EOSINOPHILIA; EOSINOPHILS; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; RETROSPECTIVE STUDIES;

EID: 44849130804     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.00976.x     Document Type: Article

References (55)

1. Sagnelli E, Stroffolini T, Mele A et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol 2005 75 (4 522 527.
2. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003 362 : 2095 2100.
3. Terasaki S, Nakanuma Y, Yamazak M, Unoura M. Eosinophilic infiltration of the liver in primary biliary cirrhosis: a morphological study. Hepatology 1993 17 : 206 211.
4. Martinez OM, Villanueva JC, Gershwin ME, Krams SM. Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepatology 1995 21 : 113 119.
5. Yamazaki K, Nakadate I, Suzuki K, Sato S, Masuda T. Eosinophilia in primary biliary cirrhosis. Am J Gastroenterol 1996 91 : 516 522.
6. Miyaguchi S, Oda M, Tamano M et al. Elevation of serum eosinophil cationic protein in primary biliary cirrhosis. Int Hepatol Commun 1994 2 : 285 288.
7. Nakamura A, Yamazaki K, Suzuki K, Sato S. Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis. Am J Gastroenterol 1997 92 : 2245 2249.
8. Kokubun M, Kuroda M, Takagi T et al. Eosinophilia in primary biliary cirrhosis (in Japanese). Nippon Shokakibyo Gakkai Zasshi (Jpn J Gastroenterol) 1990 87 : 1410 1416.
9. Wirth HP, Heer P, Bertschinger P, Meyenberger C, Ammann R, Altorfer J. Transient eosinophilia in primary biliary cirrhosis (in German). Schweiz Med Wochenschr 1993 123 : 2278 2283.
10. Hartleb M, Kajor M, Kaczor R, Nowak A. Hepatic eosinophilic infiltration in primary sclerosing cholangitis (letter to the editor). J Gastroenterol 1998 33 : 134 135.
11. Scheurlen M, Mork H, Weber P. Hypereosinophilic syndrome resembling chronic inflammatory bowel disease with primary sclerosing cholangitis. J Clin Gastroenterol 1992 14 : 59 63.
12. Kagawa T, Suematsu M, Miura S, Komatsu H, Oda M, Tsuchiya M. A case of primary sclerosing cholangitis with eosinophilia (in Japanese). Sogorinsho 1988 9 : 2339 2342.
13. Dillon JF, Finlayson NDC. Idiopathic hypereosinophilic sindrome presenting as intrahepatic cholestatic jaundice. Am J Gastroenterol 1994 89 : 1254 1255.
14. Foong A, Scholes JV, Gleich GJ, Kephart GM, Holt PR. Eosinophil induced chronic active hepatitis in the idiopathic hypereosinophilic syndrome. Hepatology 1991 13 : 1090 1094.
15. Croffy B, Kopelman R, Kaplan M. Hypereosinophilic syndrome. Association with chronic active hepatitis. Dig Dis Sci 1988 33 : 233 239.
16. Ho KKL, Ho ASS, Leung RCC, Lai CKW, Lai KN. The interleukin-5 messenger RNA expression in a patient with idiopathic hypereosinophilic syndrome. Clin Exp Allergy 1998 28 : 889 892.
17. Martinez OM, Ascher NL, Ferrell L et al. Evidence for a nonclassical pathway of graft rejection involving interleukin 5 and eosinophils. Transplantation 1993 55 : 909 918.
18. Foster PF, Bhattacharyya A, Sankary HN, Coleman J, Ashmann M, Williams JW. Eosinophil cationic protein's role in human hepatic allograft rejection. Hepatology 1991 13 : 1117 1125.
19. Hughes VF, Trull AK, Joshi O, Alexander JM. Monitoring eosinophil activation and liver function after liver transplantation. Transplantation 1998 65 : 1334 1339.
20. Groen PC, Kephart GM, Gleich GJ, Ludwig J. The eosinophil as an effector cell of the immune response during hepatic allograft rejection. Hepatology 1994 20 : 654 662.
21. Ben-Ari Z, Dhillon AP, Moqbel R et al. Monoclonal antibodies against eosinophils in liver allograft rejection. Liver Transpl Surg 1996 2 : 46 51.
22. Lang T, Krams SM, Berquist W, Cox KL, Esquivel CO, Martinez OM. Elevated biliary interleukin 5 as an indicator of liver allograft rejection. Transpl Immunol 1995 3 : 291 298.
23. Nagrai A, Ben-Ari Z, Dhillon AP, Burroughs AK. Eosinophils in acute cellular rejection in liver allografts. Liver Transpl Surg 1998 4 : 355 362.
24. Dollinger MM, Plevris JN, Bouchier IA, Harrison DJ, Hayes PC. Peripheral eosinophil count both before and after liver transplantation predicts acute cellular rejection. Liver Transpl Surg 1997 3 : 112 117.
25. Ben-Ari Z, Booth JD, Gupta SD, Rolles K, Dhillon AP, Burroughs AK. Morphometric image analysis and eosinophil counts in human liver allografts. Transpl Int 1995 8 : 346 352.
26. Foster PF, Sankary HN, Williams JW, Bhattacharyya A, Coleman J, Ashmann M. Morphometric inflammatory cell analysis of human liver allograft biopsies. Transplantation 1991 51 : 873 876.
27. Nonomura A, Kono N, Mizukami Y, Nakamura Y. Histological changes of the liver in experimental graft-versus-host disease across minor histocompatibility barriers. VIII. Role of eosinophil infiltration. Liver 1996 16 : 42 47.
28. Scheuer PJ, Lefkowitch JH. Drugs and Toxins: Liver Biopsy Interpretation, 5th edn. London : W.B. Saunders, 1994 : 102 116.
29. McMaster KR, Hennigar GR. Drug-induced granulomatous hepatitis. Lab Invest 1981 44 : 61 73.
30. Mullick FG, Ishak KG. Hepatic injury associated with diphenylhydantoin therapy. A clinicopathologic study of 20 cases. Am J Clin Pathos 1980 74 : 442 452.
31. Navarro VJ, Senior JR. Drug related Hepatotoxicity. N Engl J Med 2006 354 : 731 739.
32. Allam JP, Paus T, Reichel C, Bieber T, Novak N. Dress syndrome associated with carbamazepine and phenytoin. Eur J Dermatol 2004 14 : 339 342.
33. Trak-Smayra V, Cazals-Hatem D, Asselah T, Duchatelle V, Degott C. Prolonged cholestasis and ductopenia associated with tenoxicam. J Hepatol 2003 39 : 125 128.
34. Bjornsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Therap 2007 25 : 1411 1421.
35. Tsuda K, Maeda T, Tominaga A et al. Eosinophil-induced liver injury: an experimental model using a IL-5 transgenic mice. J Hepatol 2001 34 : 270 277.
36. Takahashi Y, Fukusato T, Kobayashi Y et al. High expression of eosinophil chemoattranctant ecalectin/galectin-9 in drug-induced liver injury. Liver Int 2006 26 : 106 115.
37. Hirashima M et al. Ecalectin as a T cell-derived eosinophil chemoattractant. Int Arch Allergy Immunol 1999 120 (Suppl. 1 7 10.
38. Matsumoto R, Hirashima M, Kita H, Gleich GJ. Biological activities of ecalectin: a novel eosinophil-activating factor. J Immunol 2002 168 : 1961 1967.
39. Matthews DR, Hosker JP, Rudenski AS, Turner RC, Naylor BA, Treacher DF. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 : 412 419.
40. Ikeda Y, Suehiro T, Nakamura T, Kumon Y, Hashimoto K. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J 2001 48 : 81 86.
41. Scheuer PJ, Lefkowitch JH. Liver Biopsy Interpretation. London : W.B. Saunders, 2000 294.
42. SAS Technical Report. SAS/STASSsoftware: Changes & Enhancement, release 6.07. Cary, NC : SAS Institute Inc., 1992.
43. Camma' C, Bruno S, Di Marco V et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006 43 : 64 71.
44. Gleish GJ, Flavaham NA, Fujiwara T, Vanhoutten PM. The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperactivity. J Allergy Clin Immunol 1998 81 : 776 781.
45. Yamazaki K, Suzuki K, Nakamura A et al. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology 1999 30 : 71 78.
46. Bugianesi E, Marchesini G, Gentilcore E et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006 44 (6 1648 1655.
47. Lo Iacono O, Venezia G, Petta S et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007 25 : 1181 1191.
48. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005 54 : 1003 1008.
49. Shintani Y, Fujie H, Miyoshi H et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004 126 : 840 848.
50. Miyoshi H, Fujie H, Shintani Y et al. Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression. J Hepatol 2005 43 : 757 763.
51. Kawaguchi T, Yoshida T, Harada M et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004 165 : 1499 1508.
52. Schmauder-Chock EA, Chock SP, Patchen ML. Ultrastructural localization of tumour necrosis factor-alpha. Histochem J 1994 26 (2 142 151.
53. Beil WJ, Weller PF, Tzizik DM, Galli SJ, Dvorak AM. Ultrastructural immunogold localization of tumor necrosis factor-alpha to the matrix compartment of eosinophil secondary granules in patients with idiopathic hypereosinophilic syndrome. J Histochem Cytochem 1993 41 (11 1611 1615.
54. Fehrenbach H, Weiskirchen R, Kasper M, Gressner AM. Up-regulated expression of the receptor for advanced glycation and products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology 2001 34 : 943 952.
55. Pham BN, Bemuau J, Durand F et al. Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease. J Hepatol 2001 34 : 537 547.